SavedAdd your journal

Journals / Journal of Microbiology and Infectious Diseases / 2011 / Cilt: 1 - Sayı: 02

Successful salvage treatment of Lecythophora mutabilis keratitis with topical voriconazole

Orçun Pehlivan
Şebnem Çalık
Bora Yüksel
Pages
75–77
Publication Date
2011-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Then she was treated successfully topical voriconazole.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fungal keratitis is an important ophthalmic problem in the developing world.
📊
Key Findings & Data:Filamentous fungi are the most frequently reported pathogens in fungal keratitis.
💡
Conclusion & Impact:Then she was treated successfully topical voriconazole.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Fungal keratitis is an important ophthalmic problem in the developing world. Filamentous fungi are the most frequently reported pathogens in fungal keratitis. This report aimed to present a case with Lecythophora mutabilis keratitis that treatment failure was seen with topical and systemic amphotericin B lipid complex. Then she was treated successfully topical voriconazole.

🔖

Cite This Article

Pehlivan, O., Çalık, Ş., Yüksel, B. (2011). Successful salvage treatment of Lecythophora mutabilis keratitis with topical voriconazole. Journal of Microbiology and Infectious Diseases, Cilt: 1 - Sayı: 02, 75–77. https://ajindex.com/articles/114422

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Al-Badriyeh D, Neoh CF, Stewart K, Kong DC. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis. Clin Ophthalmol 2010; 4: 391-405.
  2. Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: A review of current literature. Br J Ophthalmol 2008; 92:871– 878. Fintelmann RE, Gilmer W, Bloomer MM, Jeng BH. Recur- rent Lecythophora mutabilis keratitis and endophthalmitis after deep anterior lamellar keratoplasty. Arch Ophthalmol. 2011;129:108-110.
  3. Marcus DM, Hull DS, Rubin RM, Newman CL. Lecythophora mutabilis endophthalmitis after long-term corneal cyanoacry- late. Retina. 1999;19:351-353.
  4. Scott IU, Cruz-Villegas V, Flynn HW Jr, Miller D. Delayed-on- set, bleb-associated endophthalmitis caused by Lecythopho- ra mutabilis. Am J Ophthalmol 2004;137:583-585.
  5. Riddell J, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 2011; 52:648-653.
  6. Goldblum D, Frueh BE, Zimmerli S, Böhnke M. Treatment of post-keratitis Fusarium endophthalmitis with amphotericin B lipid complex. Cornea 2000; 19:853-857.
  7. Virata SR, Kylstra JA, Brown JC, Wohl DA, Cohen MS. Wors- ening of endogenous Candida albicans endophthalmitis dur- ing therapy with intravenous lipid complex amphotericin B. Clin Infect Dis 1999; 28:1177-1178.
  8. Al-Badriyeh D, Leung L, Davies GE, Stewart K, Kong D. Suc- cessful use of topical voriconazole 1% alone as first-line antifungal therapy against Candida albicans keratitis. Ann Pharmacother 2009;43: 2103-2107.
  9. Dupuis A, Tournier N, Le Moal G, Venisse N. Preparation and stability of voriconazole eye drop solution. Antimicrob Agents Chemother. 2009; 53:798–799.
  10. Lau D, Ferdinands M, Leung L, et al. Penetration of voricon- azole 1% eyedrops into human aqueous humor. A prospec- tive open label study. Arch Ophthalmol 2008; 126: 343-346.